Nanoform Finland, the medicine performance-enhancing company, has entered into a pre-clinical development agreement with the plasma-derived therapies business unit of Takeda to develop plasma-derived therapy formulations for the treatment of rare conditions. Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for in vivo studies. The first results of these studies are expected by earl...